CN101084020A - 放射性标记方法 - Google Patents

放射性标记方法 Download PDF

Info

Publication number
CN101084020A
CN101084020A CNA2005800441130A CN200580044113A CN101084020A CN 101084020 A CN101084020 A CN 101084020A CN A2005800441130 A CNA2005800441130 A CN A2005800441130A CN 200580044113 A CN200580044113 A CN 200580044113A CN 101084020 A CN101084020 A CN 101084020A
Authority
CN
China
Prior art keywords
compound
formula
peptide
carrier
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800441130A
Other languages
English (en)
Chinese (zh)
Inventor
E·阿斯塔
M·E·格拉泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hammersmith Imanet Ltd
Original Assignee
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hammersmith Imanet Ltd filed Critical Hammersmith Imanet Ltd
Priority to CN201510494983.3A priority Critical patent/CN105012972A/zh
Publication of CN101084020A publication Critical patent/CN101084020A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2005800441130A 2004-12-22 2005-12-09 放射性标记方法 Pending CN101084020A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510494983.3A CN105012972A (zh) 2004-12-22 2005-12-09 放射性标记方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428012.9A GB0428012D0 (en) 2004-12-22 2004-12-22 Radiolabelling methods
GB0428012.9 2004-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510494983.3A Division CN105012972A (zh) 2004-12-22 2005-12-09 放射性标记方法

Publications (1)

Publication Number Publication Date
CN101084020A true CN101084020A (zh) 2007-12-05

Family

ID=34112991

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510494983.3A Pending CN105012972A (zh) 2004-12-22 2005-12-09 放射性标记方法
CNA2005800441130A Pending CN101084020A (zh) 2004-12-22 2005-12-09 放射性标记方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510494983.3A Pending CN105012972A (zh) 2004-12-22 2005-12-09 放射性标记方法

Country Status (13)

Country Link
US (2) US7972588B2 (enExample)
EP (4) EP2266629B1 (enExample)
JP (2) JP5743372B2 (enExample)
KR (1) KR101314460B1 (enExample)
CN (2) CN105012972A (enExample)
AU (1) AU2005317903C1 (enExample)
BR (1) BRPI0519317A2 (enExample)
CA (2) CA2589136C (enExample)
GB (1) GB0428012D0 (enExample)
MX (1) MX2007007560A (enExample)
NO (1) NO341638B1 (enExample)
RU (1) RU2419627C2 (enExample)
WO (1) WO2006067376A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712603A (zh) * 2009-08-20 2012-10-03 通用电气健康护理有限公司 放射性碘标记方法
CN106458935A (zh) * 2014-01-05 2017-02-22 华盛顿大学 用于聚(adp‑核糖)聚合酶‑1(parp‑1)的放射性标记示踪物，其方法和用途
CN107007850A (zh) * 2009-12-10 2017-08-04 通用电气健康护理有限公司 碘放射性标记方法
CN107949575A (zh) * 2015-06-19 2018-04-20 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN112638415A (zh) * 2018-07-26 2021-04-09 大有华夏生物医药集团有限公司 用于成像的组合物和方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071718B2 (en) 2004-12-22 2011-12-06 General Electric Company Selective radiolabeling of biomolecules
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
EP2029616A1 (en) * 2006-06-21 2009-03-04 Hammersmith Imanet Limited Chemical methods and apparatus
US8211403B2 (en) 2006-06-21 2012-07-03 Hammersmith Imanet Limited Radiolabelling methods
EP2056886A2 (en) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-labeled peptide-based radiopharmaceuticals
WO2008025886A1 (en) * 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
EP2155259A2 (en) * 2007-05-10 2010-02-24 The Trustees of Columbia University in the City of New York Methods for diagnosing diseases and evaluating treatments therefor using pet
AU2008340449B2 (en) 2007-12-20 2014-05-22 Ge Healthcare Limited Selective radiolabeling of biomolecules
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
GB0815831D0 (en) * 2008-09-01 2008-10-08 Imp Innovations Ltd Compounds
AU2009289062B2 (en) 2008-09-05 2015-01-22 Hammersmith Imanet Limited Isatin derivatives for use as in vivo imaging agents
DK2346870T3 (en) * 2008-10-10 2015-08-17 Merck & Cie 18F-LABELED FOLATES AS PET RADIO MARKERS
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2210882A1 (en) * 2009-01-16 2010-07-28 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Synthesis of new protected azahistidine, their processes and their use in synthesises
WO2010099273A1 (en) * 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
WO2011058002A1 (en) * 2009-11-11 2011-05-19 Neurosearch A/S Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods
GB0922304D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds
WO2011079245A1 (en) * 2009-12-23 2011-06-30 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
WO2011130530A1 (en) * 2010-04-14 2011-10-20 The Mclean Hospital Corporation 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
WO2011153250A2 (en) * 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives
US10434197B2 (en) * 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
GB201014023D0 (en) * 2010-08-20 2010-10-06 Ucl Business Plc Process for producing bioconjugates and products thereof
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
GB201019824D0 (en) 2010-11-23 2011-01-05 Ge Healthcare Ltd Radioiodination method
GB201021369D0 (en) 2010-12-16 2011-01-26 Ge Healthcare Ltd Radioiodinated fatty acids
GB201021517D0 (en) 2010-12-20 2011-02-02 Ge Healthcare Ltd Radioiodinated guanidines
BR112013015798A2 (pt) 2010-12-22 2019-09-24 Ge Healthcare Ltd composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica
EP2654804A1 (en) 2010-12-22 2013-10-30 GE Healthcare UK Limited Her2 binding peptides labeled with aluminium-[18]fluoride complexed by nota
US10201625B2 (en) * 2011-03-01 2019-02-12 Imperial College Radiolabelled octreotate analogues as PET tracers
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
WO2013082508A1 (en) * 2011-12-02 2013-06-06 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
EP2809356A1 (en) * 2012-02-03 2014-12-10 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
US20160022846A1 (en) * 2014-07-22 2016-01-28 Ge Healthcare Limited Iodine radiolabelling method
WO2017023999A1 (en) * 2015-08-03 2017-02-09 Emory University Methylsulfonamide derivatives and uses related thereto
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
WO2004055160A2 (en) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
NZ520875A (en) * 2000-03-24 2005-04-29 Euro Celtique S Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
US6350360B1 (en) 2000-04-07 2002-02-26 Sandia Coroporation Method of fabricating a 3-dimensional tool master
WO2001077145A2 (en) * 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
WO2003101972A1 (en) 2002-05-30 2003-12-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
CN103215227B (zh) 2003-04-17 2015-09-16 斯克利普斯研究院 扩展真核生物遗传密码
JP5275566B2 (ja) * 2003-06-18 2013-08-28 ザ スクリプス リサーチ インスティチュート 反応性非天然アミノ酸遺伝コード付加
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
JP2008515876A (ja) * 2004-10-07 2008-05-15 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ イメージング及び治療用のイメージング及び治療のエンドキットにおけるシュタウディンガーライゲーションの使用
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
WO2004055160A2 (en) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712603A (zh) * 2009-08-20 2012-10-03 通用电气健康护理有限公司 放射性碘标记方法
CN102712603B (zh) * 2009-08-20 2015-11-25 通用电气健康护理有限公司 放射性碘标记方法
CN107007850A (zh) * 2009-12-10 2017-08-04 通用电气健康护理有限公司 碘放射性标记方法
CN106458935A (zh) * 2014-01-05 2017-02-22 华盛顿大学 用于聚(adp‑核糖)聚合酶‑1(parp‑1)的放射性标记示踪物，其方法和用途
CN106458935B (zh) * 2014-01-05 2019-05-28 华盛顿大学 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途
CN107949575A (zh) * 2015-06-19 2018-04-20 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN107949575B (zh) * 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN112638415A (zh) * 2018-07-26 2021-04-09 大有华夏生物医药集团有限公司 用于成像的组合物和方法

Also Published As

Publication number Publication date
MX2007007560A (es) 2007-11-21
CA2589136C (en) 2015-10-06
AU2005317903B2 (en) 2011-12-01
JP2008528445A (ja) 2008-07-31
BRPI0519317A2 (pt) 2009-01-13
GB0428012D0 (en) 2005-01-26
CN105012972A (zh) 2015-11-04
US7972588B2 (en) 2011-07-05
AU2005317903C1 (en) 2012-05-10
NO341638B1 (no) 2017-12-18
EP2266629A1 (en) 2010-12-29
KR101314460B1 (ko) 2013-10-10
NO20073157L (no) 2007-06-20
AU2005317903A1 (en) 2006-06-29
EP2266629B1 (en) 2015-12-09
KR20070091626A (ko) 2007-09-11
RU2007122804A (ru) 2009-01-27
JP2012254998A (ja) 2012-12-27
RU2419627C2 (ru) 2011-05-27
AU2005317903B8 (en) 2012-01-19
US8679455B2 (en) 2014-03-25
JP5743372B2 (ja) 2015-07-01
EP2275145A1 (en) 2011-01-19
WO2006067376A3 (en) 2007-07-26
WO2006067376A2 (en) 2006-06-29
CA2589136A1 (en) 2006-06-29
EP2258403A1 (en) 2010-12-08
CA2817636A1 (en) 2006-06-29
US20090311177A1 (en) 2009-12-17
EP1830890A2 (en) 2007-09-12
US20110236311A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
KR101314460B1 (ko) Ｒｇｄ-함유 펩티드의 방사성 표지된 접합체 및클릭-화학을 통한 그의 제조 방법
US8409547B2 (en) Radiolabelling methods
US20130343990A1 (en) Radiolabelled octreotate analogues as pet tracers
US8444955B2 (en) Radiofluorination methods
US20100069609A1 (en) Chemical methods and apparatus
US8216548B2 (en) Radiofluorination methods
AU2011250795A1 (en) Radiolabelling methods
HK1136587A (en) Chemical methods and apparatus
HK1087928A1 (zh) 生物活性载体的放射氟化方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20071205